Latest Breaking News On - Mary jessel - Page 1 : comparemela.com

First Patient Dosed in U S Expanded Access Program for TLX250-CDx, Telix s Breakthrough Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ClinicalTrials.gov ID: NCT06090331) for TLX250-CDx (89Zr-DFO-girentuximab). TLX250-CDx is the Company's first-in-class, non-invasive investigational positron emission tomography (PET) imaging agent in clear cell renal cell carcinoma (ccRCC).

United statesUnited kingdomMary jesselKyahn williamsonJohn leahyDrug administrationHealth canadaCorporate communicationsTelix pharmaceuticalsAustralian therapeutic goods administrationImaging at austin radiological association inGlobal medical affairs at telixAustralian securities exchangeAustin radiological associationPrincipal investigatorSenior vice president

First Patient Dosed in U S Expanded Access Program for TLX250-CDx, Telix s Breakthrough Kidney Cancer Imaging Agent

First Patient Dosed in U S Expanded Access Program for TLX250-CDx, Telix s Breakthrough Kidney Cancer Imaging Agent
fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomKyahn williamsonMary jesselJohn leahyHealth canadaCorporate communicationsTelix pharmaceuticalsDrug administrationGlobal medical affairs at telixImaging at austin radiological association inAustralian securities exchangeAustralian therapeutic goods administrationTelix pharmaceuticals limitedAustin radiological associationPrincipal investigator